正海生物(300653) - 2024年8月6日投资者关系活动记录表

Financial Performance - The company achieved total revenue of approximately CNY 198 million in the first half of 2024, a decrease of 11.80% compared to the same period last year [3] - The net profit attributable to shareholders was approximately CNY 86.03 million, down 21.63% year-on-year [3] - Earnings per share were CNY 0.48, reflecting a decrease of 21.31% from the previous year [4] Product Sales - Sales revenue from oral repair membrane products was CNY 95.66 million, a decline of 9.80% year-on-year [4] - Sales revenue from absorbable dura mater patches and dura mater patches reached CNY 75.81 million, down 16.63% compared to the previous year [4] Marketing and R&D Efforts - The company is actively implementing precision marketing strategies and increasing market expansion efforts [5] - Successful bids in centralized procurement for dura mater products in Hebei and Shandong provinces were achieved [5] - Key progress was made in R&D, with calcium silicate bio-ceramic bone repair materials completing clinical trial follow-ups [6] Market Challenges and Strategies - The company faces pressure on sales from centralized procurement policies, particularly in the first half of 2024 [8] - The implementation of centralized procurement policies has significantly reduced costs for dental implants, intensifying competition in the private dental sector [8] - The company is optimizing marketing strategies for oral products in the implant sector, resulting in a year-on-year increase in sales volume [8] Future Product Development - The company is advancing its product development strategy, with calcium silicate bio-ceramic bone repair materials expected to submit registration in the second half of the year [10] - The oral pipeline bio-repair membrane is currently in the registration phase, aiming to enhance product competitiveness [10] Collaboration and Innovation - A technical development project with Jiangsu Jicui is underway to develop high-end medical devices using recombinant active biological proteins [12] - The project is in its early stages, with plans to expand the application of scaffold materials in the tissue engineering field [12]